Newsletter Newsletters Events Events Podcasts Videos Africanews
Loader
Latest
Trending
Latest stories
Europe
Categories
Programmes
Featured
World
Categories
Programmes
Featured
EU Policy
Business
Categories
Programmes
Featured
Travel
Categories
Programmes
Next
Categories
Programmes
Featured
Culture
Categories
Programmes
Green
Categories
Programmes
Featured
Health
Categories
Programmes
Euroviews
Videos
More
Special coverage
Partner content
Services
Newsletter Newsletters Events Events Podcasts Videos Africanews
Loader
Find Us
Flipboard Instagram Linkedin
Advertisement

Bayer to sell Nebido testosterone treatment in deal worth up to $500 million

Bayer to sell Nebido testosterone treatment in deal worth up to $500 million
Bayer to sell Nebido testosterone treatment in deal worth up to $500 million -  Copyright  Thomson Reuters 2022
Copyright Thomson Reuters 2022
By Reuters
Published on
Share Comments
Share Close Button

BERLIN - Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday.

The deal, which Bayer said would help it focus its Pharma business on key areas of future medical innovation, is expected to close by the end of 2022, according to the company.

($1 = 0.9981 euros)

Go to accessibility shortcuts
Share Comments

Read more